Small interfering RNA (siRNA) has been expected to be a unique pharmaceutic for the
treatment of broad-spectrum intractable diseases. However, its unfavorable properties such …

The first closed bilayer phospholipid systems, called liposomes, were described in 1965 and
soon were proposed as drug delivery systems. The pioneering work of countless liposome …

Gene and nucleic acid therapy is expected to play a major role in the next generation of
agents for cancer treatment. We have recently developed a multifunctional envelope-type …

Neuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique
features of this type of cancer frequently hamper the process of determining clinical …

Technological advances in both siRNA (small interfering RNA) and whole genome
sequencing have demonstrated great potential in translating genetic information into siRNA …

Angiogenesis is a process of generation of de-novo blood vessels from already existing
vasculature. It has a crucial role in different physiological process including wound healing …

According to a 2020 World Health Organization report (Globocan 2020), cancer was a
leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The aim …

Therapeutics based on small interfering RNA (siRNA) have a huge potential for the
treatment of disease but requires sophisticated delivery systems for in vivo applications …

Ganglioside GD2 is highly expressed on neuroectoderm-derived tumors and sarcomas,
including neuroblastoma, retinoblastoma, melanoma, small cell lung cancer, brain tumors …

Monoclonal antibodies (mAbs) are an important class of therapeutic agents approved for the
therapy of many types of malignancies. However, in certain cases applications of …